Compare Sincere Co., Ltd. (Japan) with Similar Stocks
Dashboard
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 45.32
2
Healthy long term growth as Operating profit has grown by an annual rate 21.19%
3
The company has declared Negative results for the last 3 consecutive quarters
4
With ROE of 10.02%, it has a very attractive valuation with a 1.12 Price to Book Value
5
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
JPY 3,163 Million (Micro Cap)
11.00
NA
0.00%
0.05
9.31%
1.14
Revenue and Profits:
Net Sales:
1,935 Million
(Quarterly Results - Mar 2026)
Net Profit:
68 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.22%
0%
-0.22%
6 Months
-12.62%
0%
-12.62%
1 Year
-21.07%
0%
-21.07%
2 Years
-0.44%
0%
-0.44%
3 Years
-25.2%
0%
-25.2%
4 Years
2.93%
0%
2.93%
5 Years
-29.91%
0%
-29.91%
Sincere Co., Ltd. (Japan) for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.23%
EBIT Growth (5y)
21.19%
EBIT to Interest (avg)
45.32
Debt to EBITDA (avg)
0.60
Net Debt to Equity (avg)
0.16
Sales to Capital Employed (avg)
1.43
Tax Ratio
32.77%
Dividend Payout Ratio
41.75%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.92%
ROE (avg)
8.80%
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
1.12
EV to EBIT
6.07
EV to EBITDA
5.14
EV to Capital Employed
1.12
EV to Sales
0.43
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
18.43%
ROE (Latest)
10.02%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
1,935.40
2,036.80
-4.98%
Operating Profit (PBDIT) excl Other Income
163.60
150.40
8.78%
Interest
6.50
5.70
14.04%
Exceptional Items
1.90
-62.40
103.04%
Consolidate Net Profit
68.50
17.20
298.26%
Operating Profit Margin (Excl OI)
74.00%
63.60%
1.04%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -4.98% vs 9.05% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 298.26% vs -77.75% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
7,456.10
6,539.40
14.02%
Operating Profit (PBDIT) excl Other Income
619.40
564.60
9.71%
Interest
22.90
16.90
35.50%
Exceptional Items
-66.50
2.80
-2,475.00%
Consolidate Net Profit
264.30
309.10
-14.49%
Operating Profit Margin (Excl OI)
70.30%
74.10%
-0.38%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 14.02% vs 9.69% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -14.49% vs 4.60% in Dec 2024
About Sincere Co., Ltd. (Japan) 
Sincere Co., Ltd. (Japan)
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






